A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Inclusion Criteria:

* Are on stable incretin therapy at screening
* With persistent obesity or overweight defined as:

  * ≥30 kg/m2 OR
  * ≥27 kg/m2 with at least one existing obesity related complication at screening:

    * hypertension
    * dyslipidemia
    * obstructive sleep apnea
    * cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
    * type 2 diabetes
* Have a stable body weight (\<5% body weight change) at screening

Exclusion Criteria:

* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes
* Have taken any of the following antihyperglycemic medications within 90 days before screening:

  * dipeptidyl peptidase-4 (DPP-4) inhibitors
  * amylin analogs
  * insulin
* Have had within 90 days prior to screening:

  * heart attack
  * stroke
  * coronary artery revascularization
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure